Wednesday, September 7, 2011

Exelixis to report important cancer trial data in Q4

Exelixis Inc. will report initial data from an important cancer trial in the fourth quarter, the company said Wednesday.
The South San Francisco drug developer said it hit a pre-set number of “events” in its Phase III trial of its drug, cabozantinib, in patients with medullary thyroid cancer.

No comments:

Post a Comment